KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other financing activities: 2011-2013

Historic Other financing activities for Supernus Pharmaceuticals (SUPN) over the last 3 years, with Sep 2013 value amounting to $29,000.

  • Supernus Pharmaceuticals' Other financing activities rose 81.25% to $29,000 in Q3 2013 from the same period last year, while for Sep 2013 it was $6.8 million, marking a year-over-year increase of 124.83%. This contributed to the annual value of $3.6 million for FY2013, which is 39.99% down from last year.
  • According to the latest figures from Q3 2013, Supernus Pharmaceuticals' Other financing activities is $29,000, which was down 99.16% from $3.5 million recorded in Q2 2013.
  • In the past 5 years, Supernus Pharmaceuticals' Other financing activities ranged from a high of $3.5 million in Q2 2013 and a low of -$1.7 million during Q1 2011.
  • Over the past 3 years, Supernus Pharmaceuticals' median Other financing activities value was $129,000 (recorded in 2011), while the average stood at $700,364.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Other financing activities surged by 2,346.51% in 2012, and later slumped by 81.32% in 2013.
  • Quarterly analysis of 3 years shows Supernus Pharmaceuticals' Other financing activities stood at $129,000 in 2011, then soared by 2,346.51% to $3.2 million in 2012, then skyrocketed by 81.25% to $29,000 in 2013.
  • Its last three reported values are $29,000 in Q3 2013, $3.5 million for Q2 2013, and $125,000 during Q1 2013.